Thus far, only a few pan-PI3K inhibitors (buparlisib, pilaralisib and sonolisib) and dual PI3K/mTOR inhibitors (paxalisib, dactolisib, voxtalisib, PQR309) have been evaluated in clinical trials for the treatment of GBM (Table 1and Table 2), among which, buparlisib is the most commonly studied. The gene discussed is MTOR; the disease is glioblastoma.